Eble JN, Sauter G., Epstein JI, Sesterhenn IA - iarc

1816. Moudouni SM, En-Nia I, Rioux-
Leclerq N, Guille F, Lobel B (2001).
Leiomyosarcoma of the renal pelvis. Scand
J Urol Nephrol 35: 425-427.
1817. Moul JW, McCarthy WF, Fernandez
EB, Sesterhenn IA (1994). Percentage of
embryonal carcinoma and of vascular
invasion predicts pathological stage in
clinical stage I nonseminomatous testicular
cancer. Cancer Res 54: 362-364.
1818. Moul JW, Theune SM, Chang EH
(1992). Detection of RAS mutations in
archival testicular germ cell tumors by
polymerase chain reaction and oligonucleotide
hybridization. Genes
Chromosomes Cancer 5: 109-118.
1819. Moulopoulos A, Dubrow R, David C,
Dimopoulos MA (1991). Primary renal carcinoid:
computed tomography, ultrasound,
and angiographic findings. J Comput
Assist Tomogr 15: 323-325.
1820. Mourad WA, Khalil S, Radwi A,
Peracha A, Ezzat A (1998). Primary T-cell
lymphoma of the urinary bladder. Am J
Surg Pathol 22: 373-377.
1821. Mouradian JA, Coleman JW,
McGovern JH, Gray GF (1974). Granular
cell tumor (myoblastoma) of the bladder. J
Urol 112: 343-345.
1822. Mucci NR, Akdas G, Manely S, Rubin
MA (2000). Neuroendocrine expression in
metastatic prostate cancer: evaluation of
high throughput tissue microarrays to
detect heterogeneous protein expression.
Hum Pathol 31: 406-414.
1823. Muentener M, Hailemariam S, Dubs
M, Hauri D, Sulser T (2000). Primary
leiomyosarcoma of the seminal vesicle. J
Urol 164: 2027.
1824. Muir TE, Cheville JC, Lager DJ (2001).
Metanephric adenoma, nephrogenic rests,
and Wilms’ tumor: a histologic and
immunophenotypic comparison. Am J Surg
Pathol 25: 1290-1296.
1825. Mukai M, Torikata C, Iri H, Tamai S,
Sugiura H, Tanaka Y, Sakamoto M,
Hirohashi S (1992). Crystalloids in angiomyolipoma.
1. A previously unnoticed phenomenon
of renal angiomyolipoma occurring
at a high frequency. Am J Surg Pathol
16: 1-10.
1826. Mukamel E, Farrer J, Smith RB,
Dekernion JB (1987). Metastatic carcinoma
to penis: when is total penectomy indicated?
Urology 29: 15-18.
1827. Mukherjee AB, Murty VV, Rodriguez
E, Reuter VE, Bosl GJ, Chaganti RS (1991).
Detection and analysis of origin of i(12p), a
diagnostic marker of human male germ
cell tumors, by fluorescence in situ
hybridization. Genes Chromosomes
Cancer 3: 300-307.
1828. Mukhopadhyay D, Knebelmann B,
Cohen HT, Ananth S, Sukhatme VP (1997).
The von Hippel-Lindau tumor suppressor
gene product interacts with Sp1 to repress
vascular endothelial growth factor promoter
activity. Mol Cell Biol 17: 5629-5639.
1829. Mulder MP, Keijzer W, Verkerk A,
Boot AJ, Prins ME, Splinter TA, Bos JL
(1989). Activated ras genes in human seminoma:
evidence for tumor heterogeneity.
Oncogene 4: 1345-1351.
1830. Muller J, Skakkebaeck NE (1981).
Microspectrophotometric DNA measurements
of carcinoma in situ germ cells in
testis. Int J Androl 4: 211-221.
1831. Muller J, Skakkebaek NE (1984).
Testicular carcinoma in situ in children
with the androgen insensitivity (testicular
feminisation) syndrome. Br Med J (Clin Res
Ed) 288: 1419-1420.
1832. Muller J, Skakkebaek NE, Parkinson
MC (1987). The spermatocytic seminoma:
views on pathogenesis. Int J Androl 10:
147-156.
1833. Muller J, Skakkebaek NE, Ritzen M,
Ploen L, Petersen KE (1985). Carcinoma in
situ of the testis in children with 45,X/46,XY
gonadal dysgenesis. J Pediatr 106: 431-436.
1834. Munoz JJ, Ellison LM (2000). Upper
tract urothelial neoplasms: incidence and
survival during the last 2 decades. J Urol
164: 1523-1525.
1835. Murad T, Komaiko W, Oyasu R, Bauer
K (1991). Multilocular cystic renal cell carcinoma.
Am J Clin Pathol 95: 633-637.
1836. Murai Y (2001). Malignant mesothelioma
in Japan: analysis of registered
autopsy cases. Arch Environ Health 56: 84-
88.
1837. Murphy DP, Pantuck AJ, Amenta PS,
Das KM, Cummings KB, Keeney GL, Weiss
RE (1999). Female urethral adenocarcinoma:
immunohistochemical evidence of
more than 1 tissue of origin. J Urol 161:
1881-1884.
1838. Murphy G, Ragde H, Kenny G, Barren
R3rd, Erickson S, Tjoa B, Boynton A,
Holmes E, Gilbaugh J, Douglas T (1995).
Comparison of prostate specific membrane
antigen, and prostate specific antigen levels
in prostatic cancer patients. Anticancer
Res 15: 1473-1479.
1839. Murphy GP, Barren RJ, Erickson SJ,
Bowes VA, Wolfert RL, Bartsch G, Klocker
H, Pointner J, Reissigl A, McLeod DG,
Douglas T, Morgan T, Kenny GM, Ragde H,
Boynton AL, Holmes EH (1996). Evaluation
and comparison of two new prostate carcinoma
markers. Free-prostate specific antigen
and prostate specific membrane antigen.
Cancer 78: 809-818.
1840. Murphy GP, Busch C, Abrahamsson
PA, Epstein JI, McNeal JE, Miller GJ,
Mostofi FK, Nagle RB, Nordling S,
Parkinson C (1994). Histopathology of localized
prostate cancer. Consensus
Conference on Diagnosis and Prognostic
Parameters in Localized Prostate Cancer.
Stockholm, Sweden, May 12-13, 1993.
Scand J Urol Nephrol Suppl 162: 7-42.
1841. Murphy GP, Holmes EH, Boynton AL,
Kenny GM, Ostenson RC, Erickson SJ,
Barren RJ (1995). Comparison of prostate
specific antigen, prostate specific membrane
antigen, and LNCaP-based enzymelinked
immunosorbent assays in prostatic
cancer patients and patients with benign
prostatic enlargement. Prostate 26: 164-
168.
1842. Murphy GP, Tino WT, Holmes EH,
Boynton AL, Erickson SJ, Bowes VA,
Barren RJ, Tjoa BA, Misrock SL, Ragde H,
Kenny GM (1996). Measurement of
prostate-specific membrane antigen in the
serum with a new antibody. Prostate 28:
266-271.
1843. Murphy WM (1989). Urologic
Pathology. WB Saunders: Philadelphia.
1844. Murphy WM (1997). Diseases of the
urinary bladder, urethra, ureters, and renal
pelvis. In: Urological Pathology, WM
Murphy, ed. 2 nd Edition. WB Saunders:
Philadelphia, PA, pp. 87-90.
1845. Murphy WM, Beckwith JB, Farrow
GM (1994). Atlas of Tumour Pathology.
Tumours of the Kidney, Bladder, and
Related Urinary Structures. 3 rd Edition.
AFIP: Washington, DC.
1846. Murphy WM, Busch C, Algaba F
(2000). Intraepithelial lesions of urinary
bladder: morphologic considerations.
Scand J Urol Nephrol Suppl 205: 67-81.
1847. Murphy WM, Dean PJ, Brasfield JA,
Tatum L (1986). Incidental carcinoma of
the prostate. How much sampling is adequate?
Am J Surg Pathol 10: 170-174.
1848. Murphy WM, Deana DG (1992). The
nested variant of transitional cell carcinoma:
a neoplasm resembling proliferation
of Brunn’s nests. Mod Pathol 5: 240-243.
1849. Murphy WM, Miller AW (1984).
Bladder Cancer. Williams & Wilkins:
Baltimore, MD.
1850. Murphy WM, Nagy GK, Rao MK,
Soloway MS, Parija GC, Cox CE, Friedell
GH (1979). “Normal” urothelium in
patients with bladder cancer: a preliminary
report from the National Bladder
Cancer Collaborative Group A. Cancer 44:
1050-1058.
1851. Murphy WM, Soloway MS (1982).
Urothelial dysplasia. J Urol 127: 849-854.
1852. Murphy WM, Soloway MS, Barrows
GH (1991). Pathologic changes associated
with androgen deprivation therapy for
prostate cancer. Cancer 68: 821-828.
1853. Murty VV, Bosl GJ, Houldsworth J,
Meyers M, Mukherjee AB, Reuter V,
Chaganti RS (1994). Allelic loss and
somatic differentiation in human male
germ cell tumors. Oncogene 9: 2245-2251.
1854. Murty VV, Dmitrovsky E, Bosl GJ,
Chaganti RS (1990). Nonrandom chromosome
abnormalities in testicular and
ovarian germ cell tumor cell lines. Cancer
Genet Cytogenet 50: 67-73.
1855. Murty VV, Houldsworth J, Baldwin
S, Reuter V, Hunziker W, Besmer P, Bosl
G, Chaganti RS (1992). Allelic deletions in
the long arm of chromosome 12 identify
sites of candidate tumor suppressor
genes in male germ cell tumors. Proc Natl
Acad Sci USA 89: 11006-11010.
1856. Murty VV, Li RG, Houldsworth J,
Bronson DL, Reuter VE, Bosl GJ, Chaganti
RS (1994). Frequent allelic deletions and
loss of expression characterize the DCC
gene in male germ cell tumors. Oncogene
9: 3227-3231.
1857. Murty VV, Li RG, Mathew S, Reuter
VE, Bronson DL, Bosl GJ, Chaganti RS
(1994). Replication error-type genetic
instability at 1q42-43 in human male germ
cell tumors. Cancer Res 54: 3983-3985.
1858. Muscheck M, Abol-Enein H, Chew
K, Moore D, Bhargava V, Ghoneim MA,
Carroll PR, Waldman FM (2000).
Comparison of genetic changes in schistosome-related
transitional and squamous
bladder cancers using comparative
genomic hybridization. Carcinogenesis
21: 1721-1726.
1859. Mustacchi P, Shimkin MS (1958).
Cancer of the bladder and infestation with
Schistosoma Haematobium. J Natl
Cancer Inst 20: 825-842.
1860. Mydlo JH, Bard RH (1987). Analysis
of papillary renal adenocarcinoma.
Urology 30: 529-534.
1861. Nabi G, Ansari MS, Singh I, Sharma
MC, Dogra PN (2001). Primary squamous
cell carcinoma of the prostate: a rare clinicopathological
entity. Report of 2 cases
and review of literature. Urol Int 66: 216-
219.
1862. Nadji M, Morales AR (1983).
Immunohistochemical markers for prostatic
cancer. Ann N Y Acad Sci 420: 134-
139.
1863. Nadji M, Tabei SZ, Castro A, Chu
TM, Murphy GP, Wang MC, Morales AR
(1981). Prostatic-specific antigen: an
immunohistologic marker for prostatic
neoplasms. Cancer 48: 1229-1232.
1864. Nagashima Y, Miyagi Y, Udagawa K,
Taki A, Misugi K, Sakai N, Kondo K, Kaneko
S, Yao M, Shuin T (1996). Von Hippel-Lindau
tumour suppressor gene. Localization of
expression by in situ hybridization. J Pathol
180: 271-274.
1865. Nagashima Y, Ohaki Y, Tanaka Y,
Misugi K, Horiuchi M (1988). A case of renal
angiomyolipomas associated with multiple
and various hamartomatous microlesions.
Virchows Arch A Pathol Anat Histopathol
413: 177-182.
1866. Nagy GK, Frable WJ, Murphy WM
(1982). Classification of premalignant urothelial
abnormalities. A Delphi study of the
National Bladder Cancer Collaborative
Group A. Pathol Annu 17 (Pt 1): 219-233.
1867. Nakai Y, Namba Y, Sugao H (1999).
Renal lymphangioma. J Urol 162: 484-485.
1868. Nakashima N, Murakami S, Fukatsu T,
Nagasaka T, Fukata S, Ohiwa N, Nara Y,
Sobue M, Takeuchi J (1988). Characteristics
of “embryoid body” in human gonadal germ
cell tumors. Hum Pathol 19: 1144-1154.
1869. Narducci MG, Fiorenza MT, Kang SM,
Bevilacqua A, di Giacomo M, Remotti D,
Picchio MC, Fidanza V, Cooper MD, Croce
CM, Mangia F, Russo G (2002). TCL1 participates
in early embryonic development and is
overexpressed in human seminomas. Proc
Natl Acad Sci USA 99: 11712-11717.
1870. Narla G, Heath KE, Reeves HL, Li D,
Giono LE, Kimmelman AC, Glucksman MJ,
Narla J, Eng FJ, Chan AM, Ferrari AC,
Martignetti JA, Friedman SL (2001). KLF6, a
candidate tumor suppressor gene mutated in
prostate cancer. Science 294: 2563-2566.
1871. Nasca MR, Innocenzi D, Micali G
(1999). Penile cancer among patients with
genital lichen sclerosus. J Am Acad
Dermatol 41: 911-914.
1872. Nassiri M, Ghazi C, Stivers JR, Nadji M
(1994). Ganglioneuroma of the prostate. A
novel finding in neurofibromatosis. Arch
Pathol Lab Med 118: 938-939.
1873. Nativ O, Winkler HZ, Reiman HRJr,
Earle JD, Lieber MM (1997). Primary testicular
seminoma: prognostic significance of
nuclear DNA ploidy pattern. Eur Urol 31: 401-
404.
1874. Navon JD, Rahimzadeh M, Wong AK,
Carpenter PM, Ahlering TE (1997).
Angiosarcoma of the bladder after therapeutic
irradiation for prostate cancer. J Urol 157:
1359-1360.
1875. Neal DE, Marsh C, Bennett MK, Abel
PD, Hall RR, Sainsbury JR, Harris AL (1985).
Epidermal-growth-factor receptors in
human bladder cancer: comparison of invasive
and superficial tumours. Lancet 1: 366-
368.
1876. Neal DE, Sharples L, Smith K, Fennelly
J, Hall RR, Harris AL (1990). The epidermal
growth factor receptor and the prognosis of
bladder cancer. Cancer 65: 1619-1625.
1877. Negri E, La Vecchia C (2001).
Epidemiology and prevention of bladder cancer.
Eur J Cancer Prev 10: 7-14.
1878. Nellist M, van Slegtenhorst MA,
Goedbloed M, van den Ouweland AM, Halley
DJ, van der Sluijs P (1999). Characterization
of the cytosolic tuberin-hamartin complex.
Tuberin is a cytosolic chaperone for
hamartin. J Biol Chem 274: 35647-35652.
1879. Nelson CP, Kidd LC, Sauvageot J,
Isaacs WB, de Marzo AM, Groopman JD,
Nelson WG, Kensler TW (2001). Protection
against 2-hydroxyamino-1-methyl-6-
phenylimidazo[4,5-b]pyridine cytotoxicity
and DNA adduct formation in human
prostate by glutathione S-transferase P1.
Cancer Res 61: 103-109.
334 References